Kiniksa Pharmaceuticals International PLC (NAS:KNSA)
$ 22.53 0.92 (4.26%) Market Cap: 1.60 Bil Enterprise Value: 1.33 Bil PE Ratio: 204.82 PB Ratio: 3.69 GF Score: 62/100

Q4 2023 Kiniksa Pharmaceuticals Ltd Earnings Call Transcript

Feb 28, 2024 / 01:30PM GMT
Release Date Price: $20.36 (-2.54%)
Operator

Good day and thank you for standing by. Welcome to the Kiniksa Pharmaceuticals' fourth quarter and full year 2023 earnings conference call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session.

(Operator Instructions) Please be advised today's conference is being recorded. I would now like to hand the conference over to your speaker today, Rachel Frank, Head of Investor Relations. Please go ahead.

Rachel Frank
Kiniksa Pharmaceuticals Ltd. - IR

Thank you, operator. Good morning, everyone, and thank you for joining Kiniksa's call to discuss our fourth quarter and full year 2023 financial results and recent portfolio execution. A press release highlighting these results can be found in our website under the investor section. After the agenda, our Chief Executive Officer, Sanj K. Patel, will start with an introduction; Ross Moat, our Chief Commercial Officer, will provide an update on our ARCALYST commercial execution; John Paolini, our Chief Medical Officer, will review

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot